{"id":77204,"date":"2026-11-18T19:17:18","date_gmt":"2026-11-18T19:17:18","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?p=77204"},"modified":"2026-11-18T19:17:18","modified_gmt":"2026-11-18T19:17:18","slug":"american-analyst-ratings-updates-november-18-2026","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/","title":{"rendered":"American Analyst Ratings Updates \u2014 November 18, 2026"},"content":{"rendered":"<h2><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/?p=77204&amp;preview=true\">Analyst Ratings (USA)<\/a><\/h2>\n<p>Wall Street analyst sentiment remains mixed, with selective optimism across technology, healthcare, energy and consumer staples, offset by increasing caution toward high-valuation growth stocks and industrial companies. Technology continues to attract interest, with Camtek upgraded to Outperform and Manhattan Associates receiving positive initial coverage, although Nvidia&#8217;s downgrade to Hold highlights concerns surrounding AI valuations and near-term momentum. Healthcare presents a divided outlook, with upgrades for Elevance Health and Tandem Diabetes Care offset by downgrades for Insulet and Summit Therapeutics. Energy sentiment is similarly mixed, with Exxon Mobil upgraded to Buy while Comstock Resources was downgraded. Consumer staples remain relatively defensive, with favourable initial ratings for Coca-Cola, Celsius, Keurig Dr Pepper and Monster Beverage. Financials showed strength, led by Charles Schwab&#8217;s upgrade to Strong Buy, while industrials and materials faced greater caution following downgrades for Eaton, GE Vernova and Freeport-McMoRan.<\/p>\n<p><strong>General Market Outlook:<\/strong> The latest analyst revisions suggest a cautiously optimistic but increasingly selective U.S. equity market. Analysts continue to favour companies with strong earnings visibility, sustainable cash flow and attractive growth prospects while becoming more cautious about elevated valuations, slowing economic growth and uncertainty surrounding interest rates. Overall, the outlook supports continued opportunities in quality growth and defensive stocks, although sector rotation and heightened volatility could limit a broad-based year-end market rally.<\/p>\n<h3><strong>Updates (259)<\/strong><\/h3>\n<p><strong>AbbVie (ABBV)<\/strong> \u2014 Piper Sandler reiterated its Overweight rating with a price target of $349.00.<\/p>\n<p><strong>AbCellera Biologics (ABCL)<\/strong> \u2014 Lake Street Capital initiated coverage with a Buy rating and a price target of $19.00.<\/p>\n<p><strong>ACADIA Pharmaceuticals (ACAD)<\/strong> \u2014 Oppenheimer lowered its price target from $23.00 to $21.00, maintaining a Market Perform rating.<\/p>\n<p><strong>Adeia (ADEA)<\/strong> \u2014 Rosenblatt Securities reiterated its Buy rating with a price target of $35.00.<\/p>\n<p><strong>Adherex Technologies (FENC)<\/strong> \u2014 HC Wainwright raised its price target from $16.00 to $17.00, maintaining a Buy rating.<\/p>\n<p><strong>AECOM (ACM)<\/strong> \u2014 Barclays raised its price target from $73.00 to $90.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>AECOM (ACM)<\/strong> \u2014 KeyCorp raised its price target from $78.00 to $97.00, maintaining an Overweight rating.<\/p>\n<p><strong>Affiliated Managers Group (AMG)<\/strong> \u2014 TD Cowen reiterated its Buy rating with a price target of $583.00.<\/p>\n<p><strong>Alnylam Pharmaceuticals (ALNY)<\/strong> \u2014 JPMorgan Chase &amp; Co. reiterated its price target with a price target of $254.00.<\/p>\n<p><strong>Alnylam Pharmaceuticals (ALNY)<\/strong> \u2014 Rodman &amp; Renshaw downgraded the stock to Neutral.<\/p>\n<p><strong>Amer Sports (AS)<\/strong> \u2014 Cantor Fitzgerald raised its price target from $46.00 to $47.00, maintaining an Overweight rating.<\/p>\n<p><strong>Amer Sports (AS)<\/strong> \u2014 UBS Group lowered its price target from $62.00 to $56.00, maintaining a Buy rating.<\/p>\n<p><strong>American Axle &amp; Manufacturing (DCH)<\/strong> \u2014 Morgan Stanley lowered its price target from $7.00 to $6.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>American Axle &amp; Manufacturing (DCH)<\/strong> \u2014 TD Cowen reiterated its Buy rating with a price target of $10.00.<\/p>\n<p><strong>Antero Resources (AR)<\/strong> \u2014 Morgan Stanley raised its price target from $51.00 to $52.00, maintaining an Overweight rating.<\/p>\n<p><strong>APA Corporation (APA)<\/strong> \u2014 Morgan Stanley raised its price target from $43.00 to $44.00, maintaining an Underweight rating.<\/p>\n<p><strong>AppLovin (APP)<\/strong> \u2014 JPMorgan Chase &amp; Co. reiterated its price target with a price target of $400.00.<\/p>\n<p><strong>Baidu (BIDU)<\/strong> \u2014 Barclays lowered its price target from $80.00 to $72.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Baidu (BIDU)<\/strong> \u2014 Stifel Nicolaus reiterated its price target with a price target of $83.00.<\/p>\n<p><strong>Baidu (BIDU)<\/strong> \u2014 Susquehanna lowered its price target from $105.00 to $75.00, maintaining a Neutral rating.<\/p>\n<p><strong>Bally&#8217;s (BALY)<\/strong> \u2014 Truist Financial lowered its price target from $10.00 to $9.00, maintaining a Hold rating.<\/p>\n<p><strong>BILL Holdings, Inc. (BILL)<\/strong> \u2014 BMO Capital Markets raised its price target from $56.00 to $68.00, maintaining a Market Perform rating.<\/p>\n<p><strong>Biogen (BIIB)<\/strong> \u2014 Needham &amp; Company LLC reiterated its Buy rating.<\/p>\n<p><strong>Bitdeer Technologies Group (BTDR)<\/strong> \u2014 StoneX lowered its price target from $22.00 to $15.00, maintaining a Buy rating.<\/p>\n<p><strong>BlackLine (BL)<\/strong> \u2014 BMO Capital Markets lowered its price target from $32.00 to $30.00, maintaining a Market Perform rating.<\/p>\n<p><strong>Bridger Aerospace Group (BAER)<\/strong> \u2014 Canaccord Genuity Group downgraded the stock from Buy to Hold, with a price target of $1.00.<\/p>\n<p><strong>Bridger Aerospace Group (BAER)<\/strong> \u2014 Stifel Nicolaus downgraded the stock from Buy to Hold, with a price target of $0.25.<\/p>\n<p><strong>BrightSpring Health Services (BTSG)<\/strong> \u2014 BMO Capital Markets raised its price target from $80.00 to $84.00, maintaining an Outperform rating.<\/p>\n<p><strong>Brookfield (BN)<\/strong> \u2014 Morgan Stanley lowered its price target from $54.00 to $52.00, maintaining an Overweight rating.<\/p>\n<p><strong>Brookfield Asset Management (BAM)<\/strong> \u2014 Morgan Stanley raised its price target from $54.00 to $57.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Builders FirstSource (BLDR)<\/strong> \u2014 Royal Bank Of Canada reiterated its Sector Perform rating with a price target of $56.00.<\/p>\n<p><strong>BWX Technologies (BWXT)<\/strong> \u2014 TD Cowen lowered its price target from $230.00 to $180.00, maintaining a Buy rating.<\/p>\n<p><strong>Calumet (CLMT)<\/strong> \u2014 TD Cowen lowered its price target from $40.00 to $37.00, maintaining a Hold rating.<\/p>\n<p><strong>Camtek (CAMT)<\/strong> \u2014 Northland Capital upgraded the stock from Market Perform to Outperform, with a price target of $130.<\/p>\n<p><strong>Camtek (CAMT)<\/strong> \u2014 Northland Securities upgraded the stock from Market Perform to Outperform, with a price target of $130.00.<\/p>\n<p><strong>Cardinal Health (CAH)<\/strong> \u2014 Barclays raised its price target from $275.00 to $320.00, maintaining an Overweight rating.<\/p>\n<p><strong>Caterpillar (CAT)<\/strong> \u2014 DA Davidson reiterated its price target with a price target of $685.00.<\/p>\n<p><strong>Celsius (CELH)<\/strong> \u2014 Wolfe Research initiated coverage with a Outperform rating and a price target of $39.00.<\/p>\n<p><strong>Cencora (COR)<\/strong> \u2014 Barclays raised its price target from $350.00 to $415.00, maintaining an Overweight rating.<\/p>\n<p><strong>Ceva (CEVA)<\/strong> \u2014 Rosenblatt Securities reiterated its Buy rating with a price target of $49.00.<\/p>\n<p><strong>CG Oncology (CGON)<\/strong> \u2014 Morgan Stanley raised its price target from $102.00 to $117.00, maintaining an Overweight rating.<\/p>\n<p><strong>Charles Schwab (SCHW)<\/strong> \u2014 Raymond James upgraded the stock from Outperform to Strong Buy, with a price target of $135.<\/p>\n<p><strong>Charles Schwab (SCHW)<\/strong> \u2014 Raymond James Financial upgraded the stock from Outperform to Strong-Buy, with a price target of $135.00.<\/p>\n<p><strong>Chime Financial (CHYM)<\/strong> \u2014 B. Riley Financial reiterated its Buy rating with its price target from $45.00 to $55.00.<\/p>\n<p><strong>Chord Energy (CHRD)<\/strong> \u2014 Morgan Stanley raised its price target from $178.00 to $183.00, maintaining an Overweight rating.<\/p>\n<p><strong>Chord Energy (CHRD)<\/strong> \u2014 Truist Financial reiterated its price target with a price target of $197.00.<\/p>\n<p><strong>Church &amp; Dwight (CHD)<\/strong> \u2014 Bank of America raised its price target from $115.00 to $125.00, maintaining a Buy rating.<\/p>\n<p><strong>Cleveland-Cliffs (CLF)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $17.00 to $18.00, maintaining an Overweight rating.<\/p>\n<p><strong>Climb Bio (CLYM)<\/strong> \u2014 Royal Bank Of Canada reiterated its Outperform rating with a price target of $23.00.<\/p>\n<p><strong>CNX Resources (CNX)<\/strong> \u2014 Morgan Stanley upgraded the stock from Underweight to Equal Weight and changed its price target from $34.00 to $36.00.<\/p>\n<p><strong>Coca-Cola (KO)<\/strong> \u2014 Wolfe Research initiated coverage with a Outperform rating.<\/p>\n<p><strong>Commercial Metals (CMC)<\/strong> \u2014 Wells Fargo &amp; Company lowered its price target from $70.00 to $63.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Comstock Resources (CRK)<\/strong> \u2014 Barclays downgraded the stock to Underweight.<\/p>\n<p><strong>Comstock Resources (CRK)<\/strong> \u2014 Morgan Stanley downgraded the stock from Equal Weight to Underweight, with a price target of $13.00.<\/p>\n<p><strong>ConocoPhillips (COP)<\/strong> \u2014 Morgan Stanley raised its price target from $159.00 to $160.00, maintaining an Overweight rating.<\/p>\n<p><strong>Credicorp (BAP)<\/strong> \u2014 UBS Group lowered its price target from $473.00 to $458.00, maintaining a Buy rating.<\/p>\n<p><strong>Cue Biopharma (CUE)<\/strong> \u2014 B. Riley Financial reiterated its Buy rating.<\/p>\n<p><strong>Deere &amp; Company (DE)<\/strong> \u2014 Oppenheimer reiterated its Outperform rating.<\/p>\n<p><strong>Devon Energy (DVN)<\/strong> \u2014 Morgan Stanley raised its price target from $64.00 to $65.00, maintaining an Overweight rating.<\/p>\n<p><strong>Diamondback Energy (FANG)<\/strong> \u2014 Royal Bank Of Canada reiterated its Outperform rating with a price target of $240.00.<\/p>\n<p><strong>Disc Medicine (IRON)<\/strong> \u2014 Morgan Stanley raised its price target from $92.00 to $104.00, maintaining an Overweight rating.<\/p>\n<p><strong>DLocal (DLO)<\/strong> \u2014 Truist Financial lowered its price target from $17.00 to $16.00, maintaining a Buy rating.<\/p>\n<p><strong>Docusign (DOCU)<\/strong> \u2014 BTIG Research raised its price target from $75.00 to $90.00, maintaining a Buy rating.<\/p>\n<p><strong>Duos Technologies Group (DUOT)<\/strong> \u2014 Chardan Capital lowered its price target from $9.50 to $5.50, maintaining a Neutral rating.<\/p>\n<p><strong>Dutch Bros (BROS)<\/strong> \u2014 Guggenheim lowered its price target from $76.00 to $62.00, maintaining a Buy rating.<\/p>\n<p><strong>Eaton (ETN)<\/strong> \u2014 Erste Group Bank downgraded the stock from Buy to Hold.<\/p>\n<p><strong>Ecolab (ECL)<\/strong> \u2014 Oppenheimer raised its price target from $320.00 to $331.00, maintaining an Outperform rating.<\/p>\n<p><strong>Ecolab (ECL)<\/strong> \u2014 Robert W. Baird raised its price target from $317.00 to $324.00, maintaining an Outperform rating.<\/p>\n<p><strong>Ecolab (ECL)<\/strong> \u2014 Stifel Nicolaus raised its price target from $337.00 to $356.00, maintaining a Buy rating.<\/p>\n<p><strong>Eikon Therapeutics (EIKN)<\/strong> \u2014 Morgan Stanley lowered its price target to $30.00, maintaining an Overweight rating.<\/p>\n<p><strong>Elbit Systems (ESLT)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $885.00 to $900.00, maintaining a Neutral rating.<\/p>\n<p><strong>Elevance Health (ELV)<\/strong> \u2014 Argus upgraded the stock from Hold to Buy, with a price target of $510.00.<\/p>\n<p><strong>Energizer (ENR)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $22.00 to $25.00, maintaining a Neutral rating.<\/p>\n<p><strong>Energizer (ENR)<\/strong> \u2014 Morgan Stanley raised its price target from $21.00 to $27.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Energizer (ENR)<\/strong> \u2014 UBS Group raised its price target from $22.00 to $28.00, maintaining a Neutral rating.<\/p>\n<p><strong>Enovix (ENVX)<\/strong> \u2014 Bank of America downgraded the stock from Neutral to Underperform and changed its price target from $5.00 to $1.00.<\/p>\n<p><strong>Entrada Therapeutics (TRDA)<\/strong> \u2014 Guggenheim lowered its price target from $17.00 to $13.00, maintaining a Buy rating.<\/p>\n<p><strong>EOG Resources (EOG)<\/strong> \u2014 Morgan Stanley raised its price target from $163.00 to $167.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>EQT Corporation (EQT)<\/strong> \u2014 Morgan Stanley lowered its price target from $67.00 to $66.00, maintaining an Overweight rating.<\/p>\n<p><strong>Expand Energy (EXE)<\/strong> \u2014 Morgan Stanley lowered its price target from $123.00 to $120.00, maintaining an Overweight rating.<\/p>\n<p><strong>ExxonMobil (XOM)<\/strong> \u2014 Erste Group Bank upgraded the stock from Hold to Buy.<\/p>\n<p><strong>Ferguson (FERG)<\/strong> \u2014 Bank of America raised its price target from $315.00 to $320.00, maintaining a Buy rating.<\/p>\n<p><strong>Freeport-McMoRan (FCX)<\/strong> \u2014 Erste Group Bank downgraded the stock from Buy to Hold.<\/p>\n<p><strong>fuboTV (FUBO)<\/strong> \u2014 Barrington Research lowered its price target from $16.00 to $12.00, maintaining an Outperform rating.<\/p>\n<p><strong>fuboTV (FUBO)<\/strong> \u2014 BTIG Research reiterated its Neutral rating.<\/p>\n<p><strong>Futu (FUTU)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $122.00 to $103.00, maintaining a Neutral rating.<\/p>\n<p><strong>GE HealthCare Technologies (GEHC)<\/strong> \u2014 BTIG Research raised its price target from $83.00 to $91.00, maintaining a Buy rating.<\/p>\n<p><strong>GE Vernova (GEV)<\/strong> \u2014 Erste Group Bank downgraded the stock from Buy to Hold.<\/p>\n<p><strong>GeneDx (WGS)<\/strong> \u2014 BTIG Research reiterated its Buy rating with a price target of $85.00.<\/p>\n<p><strong>General Fusion Group (GFUZ)<\/strong> \u2014 Wedbush reiterated its Neutral rating with a price target of $7.00.<\/p>\n<p><strong>Generate Biomedicines (GENB)<\/strong> \u2014 Morgan Stanley lowered its price target from $22.00 to $21.00, maintaining an Overweight rating.<\/p>\n<p><strong>Geo Group (GEO)<\/strong> \u2014 JonesTrading reiterated its Buy rating with a price target of $42.75.<\/p>\n<p><strong>GH Research (GHRS)<\/strong> \u2014 Guggenheim raised its price target from $40.00 to $46.00, maintaining a Buy rating.<\/p>\n<p><strong>Granite Point Mortgage Trust (GPMT)<\/strong> \u2014 UBS Group lowered its price target to $3.00, maintaining a Neutral rating.<\/p>\n<p><strong>Gray Media (GTN)<\/strong> \u2014 Guggenheim raised its price target from $7.00 to $8.00, maintaining a Buy rating.<\/p>\n<p><strong>Greenwich LifeSciences (GLSI)<\/strong> \u2014 HC Wainwright raised its price target from $69.00 to $70.00, maintaining a Buy rating.<\/p>\n<p><strong>Guardant Health (GH)<\/strong> \u2014 TD Cowen reiterated its Buy rating.<\/p>\n<p><strong>HA Sustainable Infrastructure Capital (HASI)<\/strong> \u2014 Jefferies Financial Group reiterated its Buy rating with a price target of $46.00.<\/p>\n<p><strong>HCA Healthcare (HCA)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $425.00 to $475.00, maintaining a Neutral rating.<\/p>\n<p><strong>Hershey (HSY)<\/strong> \u2014 TD Cowen reiterated its Hold rating with a price target of $173.00.<\/p>\n<p><strong>Home Depot (HD)<\/strong> \u2014 DA Davidson raised its price target from $377.00 to $390.00, maintaining a Buy rating.<\/p>\n<p><strong>Home Depot (HD)<\/strong> \u2014 JPMorgan Chase &amp; Co. reiterated its price target with a price target of $390.00.<\/p>\n<p><strong>Home Depot (HD)<\/strong> \u2014 Mizuho lowered its price target from $390.00 to $385.00, maintaining an Outperform rating.<\/p>\n<p><strong>Home Depot (HD)<\/strong> \u2014 Royal Bank Of Canada lowered its price target from $342.00 to $334.00, maintaining a Sector Perform rating.<\/p>\n<p><strong>Home Depot (HD)<\/strong> \u2014 Sanford C. Bernstein raised its price target from $357.00 to $360.00, maintaining a Market Perform rating.<\/p>\n<p><strong>Home Depot (HD)<\/strong> \u2014 Truist Financial raised its price target from $373.00 to $376.00, maintaining a Buy rating.<\/p>\n<p><strong>Home Depot (HD)<\/strong> \u2014 UBS Group lowered its price target from $420.00 to $417.00, maintaining a Buy rating.<\/p>\n<p><strong>Hornbeck Offshore Services (HOS)<\/strong> \u2014 Pickering Energy Partners upgraded the stock from Neutral to Outperform.<\/p>\n<p><strong>Hyperfine (HYPR)<\/strong> \u2014 B. Riley Financial reiterated its Buy rating with its price target from $1.60 to $1.40.<\/p>\n<p><strong>Immix Biopharma (IMMX)<\/strong> \u2014 Mizuho lowered its price target from $23.00 to $22.00, maintaining an Outperform rating.<\/p>\n<p><strong>Immix Biopharma (IMMX)<\/strong> \u2014 Morgan Stanley raised its price target from $20.00 to $21.00, maintaining an Overweight rating.<\/p>\n<p><strong>Immunic (IMUX)<\/strong> \u2014 HC Wainwright reiterated its Buy rating.<\/p>\n<p><strong>Innoviva (INVA)<\/strong> \u2014 Piper Sandler initiated coverage with a Overweight rating and a price target of $29.00.<\/p>\n<p><strong>Insulet (PODD)<\/strong> \u2014 Stifel Nicolaus downgraded the stock from Buy to Hold and changed its price target from $180.00 to $165.00.<\/p>\n<p><strong>Intuitive Surgical (ISRG)<\/strong> \u2014 BTIG Research raised its price target from $454.00 to $513.00, maintaining a Buy rating.<\/p>\n<p><strong>Ionis Pharmaceuticals (IONS)<\/strong> \u2014 Guggenheim lowered its price target from $80.00 to $65.00, maintaining a Buy rating.<\/p>\n<p><strong>ITT Inc. (ITT)<\/strong> \u2014 TD Cowen raised its price target from $250.00 to $260.00, maintaining a Buy rating.<\/p>\n<p><strong>J. M. Smucker (SJM)<\/strong> \u2014 UBS Group raised its price target from $149.00 to $153.00, maintaining a Buy rating.<\/p>\n<p><strong>JD.com (JD)<\/strong> \u2014 Barclays lowered its price target from $38.00 to $33.00, maintaining an Overweight rating.<\/p>\n<p><strong>JD.com (JD)<\/strong> \u2014 Mizuho lowered its price target from $37.00 to $34.00, maintaining an Outperform rating.<\/p>\n<p><strong>JD.com (JD)<\/strong> \u2014 Sanford C. Bernstein lowered its price target from $40.00 to $38.00, maintaining an Outperform rating.<\/p>\n<p><strong>JD.com (JD)<\/strong> \u2014 StoneX reiterated its price target with a price target of $42.00.<\/p>\n<p><strong>Keurig Dr Pepper (KDP)<\/strong> \u2014 Wolfe Research initiated coverage with a Outperform rating and a price target of $42.00.<\/p>\n<p><strong>Klarna Group (KLAR)<\/strong> \u2014 Bank of America raised its price target from $19.00 to $20.00, maintaining a Buy rating.<\/p>\n<p><strong>Klarna Group (KLAR)<\/strong> \u2014 BMO Capital Markets lowered its price target from $14.00 to $13.00, maintaining a Market Perform rating.<\/p>\n<p><strong>Klarna Group (KLAR)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $18.00 to $17.00, maintaining a Neutral rating.<\/p>\n<p><strong>Klarna Group (KLAR)<\/strong> \u2014 Morgan Stanley lowered its price target from $17.00 to $14.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Lantern Pharma (LTRN)<\/strong> \u2014 Rodman &amp; Renshaw downgraded the stock from Buy to Neutral.<\/p>\n<p><strong>Liberty Global (LBTYA)<\/strong> \u2014 Citigroup resumed coverage with a Neutral rating and a price target of $11.00.<\/p>\n<p><strong>LifeMD (LFMD)<\/strong> \u2014 HC Wainwright lowered its price target from $9.00 to $6.00, maintaining a Buy rating.<\/p>\n<p><strong>Liftoff Mobile (LFTO)<\/strong> \u2014 UBS Group raised its price target from $25.00 to $35.00, maintaining a Buy rating.<\/p>\n<p><strong>Lowe&#8217;s Companies (LOW)<\/strong> \u2014 TD Cowen reiterated its Hold rating with a price target of $235.00.<\/p>\n<p><strong>Lowe&#8217;s Companies (LOW)<\/strong> \u2014 Truist Financial reiterated its price target with a price target of $254.00.<\/p>\n<p><strong>Lumexa Imaging (LMRI)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $19.00 to $21.00, maintaining an Overweight rating.<\/p>\n<p><strong>LuxExperience B.V. (LUXE)<\/strong> \u2014 B. Riley Financial reiterated its Buy rating with its price target from $13.00 to $14.00.<\/p>\n<p><strong>LuxExperience B.V. (LUXE)<\/strong> \u2014 TD Cowen raised its price target from $12.00 to $13.50, maintaining a Buy rating.<\/p>\n<p><strong>Manhattan Associates (MANH)<\/strong> \u2014 JPMorgan Chase &amp; Co. initiated coverage with a Overweight rating and a price target of $308.00.<\/p>\n<p><strong>MARA Holdings (MARA)<\/strong> \u2014 BTIG Research reiterated its Buy rating with a price target of $27.00.<\/p>\n<p><strong>Matador Resources (MTDR)<\/strong> \u2014 Morgan Stanley raised its price target from $69.00 to $70.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>McDonald&#8217;s (MCD)<\/strong> \u2014 KeyCorp reiterated its Overweight rating.<\/p>\n<p><strong>McKesson (MCK)<\/strong> \u2014 Barclays raised its price target from $1,000.00 to $1,235.00, maintaining an Overweight rating.<\/p>\n<p><strong>MDU Resources Group (MDU)<\/strong> \u2014 TD Cowen reiterated its Hold rating with a price target of $22.00.<\/p>\n<p><strong>Micron Technology (MU)<\/strong> \u2014 Royal Bank Of Canada reiterated its Outperform rating with a price target of $1,500.00.<\/p>\n<p><strong>Microsoft (MSFT)<\/strong> \u2014 JPMorgan Chase &amp; Co. reiterated its price target with a price target of $625.00.<\/p>\n<p><strong>Microsoft (MSFT)<\/strong> \u2014 Mizuho reiterated its price target with a price target of $625.00.<\/p>\n<p><strong>Microsoft (MSFT)<\/strong> \u2014 Oppenheimer reiterated its Outperform rating.<\/p>\n<p><strong>Microsoft (MSFT)<\/strong> \u2014 Piper Sandler reiterated its Overweight rating.<\/p>\n<p><strong>Microsoft (MSFT)<\/strong> \u2014 TD Cowen reiterated its Buy rating with a price target of $650.00.<\/p>\n<p><strong>Microsoft (MSFT)<\/strong> \u2014 UBS Group reiterated its Overweight rating.<\/p>\n<p><strong>Middleby (MIDD)<\/strong> \u2014 Oppenheimer reiterated its Outperform rating.<\/p>\n<p><strong>Midera Food Processing (MFP)<\/strong> \u2014 Robert W. Baird raised its price target from $40.00 to $43.00, maintaining a Neutral rating.<\/p>\n<p><strong>Millicom International Cellular (TIGO)<\/strong> \u2014 JPMorgan Chase &amp; Co. upgraded the stock from Neutral to Overweight, with a price target of $105.00.<\/p>\n<p><strong>Molson Coors Beverage (TAP)<\/strong> \u2014 Wolfe Research initiated coverage with a Peer Perform rating.<\/p>\n<p><strong>Monster Beverage (MNST)<\/strong> \u2014 Wolfe Research initiated coverage with a Outperform rating.<\/p>\n<p><strong>MP Materials (MP)<\/strong> \u2014 Needham resumed coverage with a Buy rating and a price target of $48.<\/p>\n<p><strong>MP Materials (MP)<\/strong> \u2014 Needham &amp; Company LLC initiated coverage with a Buy rating and a price target of $48.00.<\/p>\n<p><strong>Murphy Oil (MUR)<\/strong> \u2014 Morgan Stanley raised its price target from $37.00 to $39.00, maintaining an Underweight rating.<\/p>\n<p><strong>New York Times (NYT)<\/strong> \u2014 Citigroup downgraded the stock from Buy to Neutral and changed its price target from $85.00 to $76.00.<\/p>\n<p><strong>NIKE (NKE)<\/strong> \u2014 Barclays lowered its price target from $45.00 to $42.00, maintaining an Overweight rating.<\/p>\n<p><strong>NIKE (NKE)<\/strong> \u2014 BMO Capital Markets reiterated its Underperform rating.<\/p>\n<p><strong>NIKE (NKE)<\/strong> \u2014 BTIG Research reiterated its Buy rating.<\/p>\n<p><strong>NIKE (NKE)<\/strong> \u2014 JPMorgan Chase &amp; Co. reiterated its price target with a price target of $38.00.<\/p>\n<p><strong>NIKE (NKE)<\/strong> \u2014 Needham &amp; Company LLC reiterated its Hold rating.<\/p>\n<p><strong>Nucor (NUE)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $305.00 to $308.00, maintaining an Overweight rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Argus reiterated its Buy rating with a price target of $220.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 BMO Capital Markets reiterated its Outperform rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Citigroup reiterated its price target with a price target of $225.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 DA Davidson reiterated its Buy rating with a price target of $200.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 HSBC reiterated its price target with a price target of $170.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Jefferies Financial Group reiterated its Buy rating with its price target from $300.00 to $250.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 JPMorgan Chase &amp; Co. reiterated its Overweight rating with its price target from $215.00 to $230.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 KeyCorp reiterated its Sector Weight rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Melius Research reiterated its price target with a price target of $185.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Morgan Stanley lowered its price target from $267.00 to $260.00, maintaining an Overweight rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Needham &amp; Company LLC reiterated its Buy rating with a price target of $200.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Piper Sandler reiterated its Overweight rating with its price target from $300.00 to $230.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Royal Bank Of Canada reiterated its Outperform rating with a price target of $230.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Summit Insights downgraded the stock from Buy to Hold.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Susquehanna reiterated its Positive rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Truist Financial reiterated its price target with a price target of $174.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Wedbush raised its price target from $275.00 to $293.00, maintaining an Outperform rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Wells Fargo &amp; Company lowered its price target from $300.00 to $250.00, maintaining an Overweight rating.<\/p>\n<p><strong>Oaktree Specialty Lending (OCSL)<\/strong> \u2014 Keefe, Bruyette &amp; Woods lowered its price target from $13.50 to $12.50, maintaining a Market Perform rating.<\/p>\n<p><strong>OGE Energy (OGE)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $53.00 to $56.00, maintaining an Overweight rating.<\/p>\n<p><strong>Once Upon A Farm (OFRM)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $13.00 to $14.00, maintaining an Overweight rating.<\/p>\n<p><strong>Oncocyte (IMDX)<\/strong> \u2014 Stephens reiterated its Equal Weight rating with a price target of $4.00.<\/p>\n<p><strong>OneWater Marine (ONEW)<\/strong> \u2014 KeyCorp reiterated its Overweight rating.<\/p>\n<p><strong>Opera (OPRA)<\/strong> \u2014 B. Riley Financial lowered its price target from $28.00 to $27.00, maintaining a Buy rating.<\/p>\n<p><strong>Oric Pharmaceuticals (ORIC)<\/strong> \u2014 Wells Fargo &amp; Company lowered its price target from $25.00 to $23.00, maintaining an Overweight rating.<\/p>\n<p><strong>OrthoPediatrics (KIDS)<\/strong> \u2014 BTIG Research raised its price target from $30.00 to $40.00, maintaining a Buy rating.<\/p>\n<p><strong>Ovintiv (OVV)<\/strong> \u2014 Morgan Stanley raised its price target from $71.00 to $72.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Paysafe (PSFE)<\/strong> \u2014 Susquehanna lowered its price target from $7.00 to $3.50, maintaining a Neutral rating.<\/p>\n<p><strong>PepsiCo (PEP)<\/strong> \u2014 Wolfe Research initiated coverage with a Peer Perform rating.<\/p>\n<p><strong>Petroleo Brasileiro S.A. &#8211; Petrobras (PBR)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $24.00 to $23.50, maintaining an Overweight rating.<\/p>\n<p><strong>Phathom Pharmaceuticals (PHAT)<\/strong> \u2014 Barclays lowered its price target from $14.00 to $10.00, maintaining an Overweight rating.<\/p>\n<p><strong>Pilgrim&#8217;s Pride (PPC)<\/strong> \u2014 UBS Group raised its price target from $28.00 to $31.00, maintaining a Neutral rating.<\/p>\n<p><strong>Planet Fitness (PLNT)<\/strong> \u2014 UBS Group raised its price target from $80.00 to $83.00, maintaining a Buy rating.<\/p>\n<p><strong>Portland General Electric (POR)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $50.00 to $48.00, maintaining a Neutral rating.<\/p>\n<p><strong>Portman Ridge Finance (BCIC)<\/strong> \u2014 Keefe, Bruyette &amp; Woods lowered its price target from $7.50 to $6.50, maintaining a Market Perform rating.<\/p>\n<p><strong>Prelude Therapeutics (PRLD)<\/strong> \u2014 HC Wainwright reiterated its Buy rating with a price target of $8.00.<\/p>\n<p><strong>Procter &amp; Gamble (PG)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $180.00 to $188.00, maintaining an Overweight rating.<\/p>\n<p><strong>Pulmonx (LUNG)<\/strong> \u2014 Loop Capital reiterated its price target with a price target of $7.00.<\/p>\n<p><strong>Qualcomm (QCOM)<\/strong> \u2014 Robert W. Baird lowered its price target from $320.00 to $300.00, maintaining an Outperform rating.<\/p>\n<p><strong>Range Resources (RRC)<\/strong> \u2014 Morgan Stanley raised its price target from $45.00 to $50.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Recursion Pharmaceuticals (RXRX)<\/strong> \u2014 Morgan Stanley lowered its price target from $5.90 to $5.60, maintaining an Equal Weight rating.<\/p>\n<p><strong>Rein Therapeutics (RNTX)<\/strong> \u2014 HC Wainwright reiterated its Buy rating.<\/p>\n<p><strong>Reliance (RS)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $420.00 to $452.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Relx (RELX)<\/strong> \u2014 Erste Group Bank initiated coverage with a Buy rating.<\/p>\n<p><strong>Royalty Pharma (RPRX)<\/strong> \u2014 TD Cowen raised its price target from $68.00 to $80.00, maintaining a Buy rating.<\/p>\n<p><strong>Sabre (SABR)<\/strong> \u2014 Cantor Fitzgerald reiterated its Neutral rating with a price target of $2.00.<\/p>\n<p><strong>Salesforce (CRM)<\/strong> \u2014 BTIG Research lowered its price target from $300.00 to $250.00, maintaining a Buy rating.<\/p>\n<p><strong>Securitize (SECZ)<\/strong> \u2014 B. Riley Financial initiated coverage with a Buy rating and a price target of $14.00.<\/p>\n<p><strong>Securitize (SECZ)<\/strong> \u2014 B. Riley Securities initiated coverage with a Buy rating and a price target of $14.<\/p>\n<p><strong>ServiceTitan (TTAN)<\/strong> \u2014 Piper Sandler reiterated its Overweight rating with a price target of $110.00.<\/p>\n<p><strong>Sherwin-Williams (SHW)<\/strong> \u2014 Argus reiterated its Buy rating with a price target of $380.00.<\/p>\n<p><strong>Similarweb (SMWB)<\/strong> \u2014 Barclays raised its price target from $11.00 to $13.00, maintaining an Overweight rating.<\/p>\n<p><strong>Sinclair (SBGI)<\/strong> \u2014 Guggenheim raised its price target from $19.00 to $20.00, maintaining a Buy rating.<\/p>\n<p><strong>SKYX Platforms (SKYX)<\/strong> \u2014 Subscribe to MarketBeat All Access to unlock brokerage rankings lowered its price target from $2.50 to $2.00, maintaining a Buy rating.<\/p>\n<p><strong>SLR Investment (SLRC)<\/strong> \u2014 Keefe, Bruyette &amp; Woods lowered its price target from $13.50 to $13.00, maintaining a Market Perform rating.<\/p>\n<p><strong>Snowflake (SNOW)<\/strong> \u2014 UBS Group lowered its price target from $500.00 to $450.00, maintaining a Buy rating.<\/p>\n<p><strong>SOLV Energy (MWH)<\/strong> \u2014 UBS upgraded the stock from Neutral to Buy, with a price target of $37.<\/p>\n<p><strong>SOLV Energy (MWH)<\/strong> \u2014 UBS Group upgraded the stock from Neutral to Buy and changed its price target from $50.00 to $37.00.<\/p>\n<p><strong>Spire (SR)<\/strong> \u2014 Mizuho raised its price target from $93.00 to $96.00, maintaining an Outperform rating.<\/p>\n<p><strong>Steel Dynamics (STLD)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $271.00 to $285.00, maintaining an Overweight rating.<\/p>\n<p><strong>Stryker (SYK)<\/strong> \u2014 BTIG Research raised its price target from $304.00 to $345.00, maintaining a Buy rating.<\/p>\n<p><strong>Summit Therapeutics (SMMT)<\/strong> \u2014 Bernstein downgraded the stock from Market Perform to Underperform, with a price target of $8.30.<\/p>\n<p><strong>Summit Therapeutics (SMMT)<\/strong> \u2014 Sanford C. Bernstein downgraded the stock from Market Perform to Underperform and changed its price target from $11.90 to $8.30.<\/p>\n<p><strong>Tandem Diabetes Care (TNDM)<\/strong> \u2014 Lake Street Capital initiated coverage with a Buy rating.<\/p>\n<p><strong>Tandem Diabetes Care (TNDM)<\/strong> \u2014 Piper Sandler initiated coverage with a Neutral ? Overweight rating.<\/p>\n<p><strong>Tandem Diabetes Care (TNDM)<\/strong> \u2014 Raymond James Financial upgraded the stock from Market Perform to Strong-Buy.<\/p>\n<p><strong>Tandem Diabetes Care (TNDM)<\/strong> \u2014 Stifel Nicolaus upgraded the stock from Hold to Buy and changed its price target from $22.00 to $26.00.<\/p>\n<p><strong>Tandem Diabetes Care (TNDM)<\/strong> \u2014 UBS Group upgraded the stock from Neutral to Buy.<\/p>\n<p><strong>Tencent Music Entertainment Group (TME)<\/strong> \u2014 Mizuho lowered its price target from $15.00 to $14.00, maintaining an Outperform rating.<\/p>\n<p><strong>Tyler Technologies (TYL)<\/strong> \u2014 TD Cowen raised its price target from $450.00 to $475.00, maintaining a Buy rating.<\/p>\n<p><strong>Tyler Technologies (TYL)<\/strong> \u2014 Truist Financial reiterated its Buy rating with its price target from $440.00 to $500.00.<\/p>\n<p><strong>Tyson Foods (TSN)<\/strong> \u2014 Bank of America raised its price target from $56.00 to $65.00, maintaining a Neutral rating.<\/p>\n<p><strong>uniQure (QURE)<\/strong> \u2014 HC Wainwright lowered its price target from $80.00 to $65.00, maintaining a Buy rating.<\/p>\n<p><strong>United States Antimony (UAMY)<\/strong> \u2014 B. Riley Financial lowered its price target from $10.00 to $6.00, maintaining a Buy rating.<\/p>\n<p><strong>Vericel (VCEL)<\/strong> \u2014 BTIG Research reiterated its Neutral rating.<\/p>\n<p><strong>Veritone (VERI)<\/strong> \u2014 HC Wainwright initiated coverage with a Buy rating and a price target of $2.00.<\/p>\n<p><strong>Viking (VIK)<\/strong> \u2014 Barclays raised its price target from $102.00 to $111.00, maintaining an Overweight rating.<\/p>\n<p><strong>Viking (VIK)<\/strong> \u2014 JPMorgan Chase &amp; Co. lowered its price target from $131.00 to $122.00, maintaining an Overweight rating.<\/p>\n<p><strong>Viking (VIK)<\/strong> \u2014 Morgan Stanley raised its price target from $92.00 to $100.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Viking (VIK)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $118.00 to $120.00, maintaining an Overweight rating.<\/p>\n<p><strong>Vista Energy (VIST)<\/strong> \u2014 UBS Group raised its price target from $80.00 to $100.00, maintaining a Buy rating.<\/p>\n<p><strong>VolitionRx (VNRX)<\/strong> \u2014 Freedom Broker downgraded the stock from Buy to Hold.<\/p>\n<p><strong>Walt Disney (DIS)<\/strong> \u2014 Bank of America raised its price target from $125.00 to $135.00, maintaining a Buy rating.<\/p>\n<p><strong>Walt Disney (DIS)<\/strong> \u2014 Barclays raised its price target from $115.00 to $135.00, maintaining an Overweight rating.<\/p>\n<p><strong>Walt Disney (DIS)<\/strong> \u2014 Guggenheim raised its price target from $120.00 to $135.00, maintaining a Buy rating.<\/p>\n<p><strong>Walt Disney (DIS)<\/strong> \u2014 JPMorgan Chase &amp; Co. raised its price target from $137.00 to $140.00, maintaining an Overweight rating.<\/p>\n<p><strong>Walt Disney (DIS)<\/strong> \u2014 Needham &amp; Company LLC raised its price target from $125.00 to $135.00, maintaining a Buy rating.<\/p>\n<p><strong>Walt Disney (DIS)<\/strong> \u2014 Raymond James Financial reiterated its Outperform rating with a price target of $133.00.<\/p>\n<p><strong>Walt Disney (DIS)<\/strong> \u2014 Rosenblatt Securities raised its price target from $126.00 to $141.00, maintaining a Buy rating.<\/p>\n<p><strong>Walt Disney (DIS)<\/strong> \u2014 Wells Fargo &amp; Company raised its price target from $132.00 to $140.00, maintaining an Overweight rating.<\/p>\n<p><strong>XPENG (XPEV)<\/strong> \u2014 Barclays lowered its price target from $14.00 to $12.00, maintaining an Underweight rating.<\/p>\n<p><strong>York Space Systems (YSS)<\/strong> \u2014 Barclays lowered its price target from $11.00 to $5.00, maintaining an Equal Weight rating.<\/p>\n<p><strong>Zoom Communications (ZM)<\/strong> \u2014 BTIG Research lowered its price target from $125.00 to $115.00, maintaining a Buy rating.<\/p>\n<p><strong>Zoom Communications (ZM)<\/strong> \u2014 Rosenblatt Securities reiterated its Buy rating with a price target of $130.00.<\/p>\n<p><strong>ZoomInfo Technologies (GTM)<\/strong> \u2014 Morgan Stanley lowered its price target from $5.00 to $4.00, maintaining an Equal Weight rating.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Analyst Ratings (USA) Wall Street analyst sentiment remains mixed, with selective optimism across technology, healthcare, energy and consumer staples, offset by increasing caution toward&hellip;<\/p>\n","protected":false},"author":3,"featured_media":77209,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-77204","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>American Analyst Ratings Updates \u2014 November 18, 2026 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"American Analyst Ratings Updates \u2014 November 18, 2026\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings (USA) Wall Street analyst sentiment remains mixed, with selective optimism across technology, healthcare, energy and consumer staples, offset by increasing caution toward&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-18T19:17:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/11\/American-Analyst-Outlook_-Sector-Trends-1024x576.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"19 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"American Analyst Ratings Updates \u2014 November 18, 2026\",\"datePublished\":\"2026-11-18T19:17:18+00:00\",\"dateModified\":\"2026-11-18T19:17:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\"},\"wordCount\":3994,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\",\"name\":\"American Analyst Ratings Updates \u2014 November 18, 2026 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-11-18T19:17:18+00:00\",\"dateModified\":\"2026-11-18T19:17:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"American Analyst Ratings Updates \u2014 November 18, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"American Analyst Ratings Updates \u2014 November 18, 2026 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/","og_locale":"en_US","og_type":"article","og_title":"American Analyst Ratings Updates \u2014 November 18, 2026","og_description":"Analyst Ratings (USA) Wall Street analyst sentiment remains mixed, with selective optimism across technology, healthcare, energy and consumer staples, offset by increasing caution toward&hellip;","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2026-11-18T19:17:18+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/11\/American-Analyst-Outlook_-Sector-Trends-1024x576.png","type":"image\/png"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"19 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"American Analyst Ratings Updates \u2014 November 18, 2026","datePublished":"2026-11-18T19:17:18+00:00","dateModified":"2026-11-18T19:17:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/"},"wordCount":3994,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/","name":"American Analyst Ratings Updates \u2014 November 18, 2026 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-11-18T19:17:18+00:00","dateModified":"2026-11-18T19:17:18+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"American Analyst Ratings Updates \u2014 November 18, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/77204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=77204"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/77204\/revisions"}],"predecessor-version":[{"id":77210,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/77204\/revisions\/77210"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/77209"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=77204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=77204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=77204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}